2017 Switzerland Cancer Diagnostics Market: Emerging Cancer Diagnostics, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains—Test Volume and Sales Forecasts, Competitive Strategies, Opportunities for Suppliers

March 2017 | 535 pages | ID: 2293326F20DEN
Venture Planning Group

Abstracts

This new report from VPGMarketResearch.com provides a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines emerging trends in the cancer diagnostics market; reviews current and emerging tests; analyzes potential applications of innovative technologies; forecasts volume and sales for major cancer diagnostics tests; profiles leading market players and potential entrants; and suggests alternative market expansion strategies for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Business Opportunities and Strategic Recommendations

• Specific new product development opportunities with potentially significant market appeal during the next five years.
• Design criteria for new products.
• Alternative market penetration strategies.
• Potential market entry barriers and risks.

Cancer Diagnostic Tests Analyzed in the Report--over 200 current and emerging assays, including Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines and Immunohistochemical Stains, such as:

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Instrumentation Review

• Analysis of major immunoassay analyzers used for cancer diagnostic testing, including their operating characteristics, features and selling prices.

Technology Review

• Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, artificial intelligence, flow cytometry, biosensors, and other technologies and their potential applications for cancer diagnostic testing.
• Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
• Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

Competitive Assessments

• Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

Contains 535 pages and 70 tables

Contents

1. INTRODUCTION

2. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

A. Instrumentation
B. Reagent Kits and Test Systems/panels
C. Computers, Software and Automation
D. Auxiliary Products

3. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

4. ALTERNATIVE MARKET PENETRATION STRATEGIES

5. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

6. MOLECULAR DIAGNOSTIC TECHNOLOGY REVIEW

A. DNA Sequencing
B. DNA and RNA Probe Technologies
C. Detection Technologies
D. Biochips: Genosensors, Microarrays, and Labs on    the Chip
E. Pharmacogenomics
F. Competing/complementing
  1. MONOCLONAL ANTIBODIES/IMMUNOASSAYS
  2. RNA PROBES
  3. TWO DIMENSIONAL ELECTROPHORESIS
  4. FLOW CYTOMETRY

7. MOLECULAR DIAGNOSTIC INSTRUMENTATION REVIEW

8. MAJOR APPLICATIONS

  1. MICROBIOLOGY/INFECTIOUS DISEASES
    a. Overview
    b. Major Infectious Diseases
  AIDS/HIV

  Adenovirus
  Aeromonads
  Anthrax/Bacillus Anthracis
  Arboviruses
  Babesiosis
  Bacillary Epithelioid Angiomatosis (BEA), other Bartonella (Rochalimaea)
  Blastocystis Hominis
  Brucella
  Campylobacter
  Candida
  Chagas Disease
  Chancroid
  Chlamydia
  Clostridium Difficile
  Coronaviruses
  Coxsackieviruses
  Creutzfeldt Jakob’s Disease
  Cryptosporidium Parvum
  Cyclospora Cayetanensis
  Cytomegalovirus
  Ebola Virus
  E. Coli
  Echovirus
  Encephalitis
  Enteroviruses
  Epstein    Barr Virus
  Giardia Lamblia
  Gonorrhea
  Granuloma Inguinale
  Hantavirus
  Helicobacter Pylori
  Hepatitis
  Herpes Simplex Virus
  Human Herpes Virus 6 (HHV    6)
  Influenza Viruses
  Legionella
  Lyme Disease
  Lymphogranuloma Venereum (LGV)
  Malaria
  Measles (Rubeola)
  Meningitis
  Microsporidium
  Mononucleosis
  Mumps
  Mycoplasma
  Papillomaviruses
  Parvovirus B19
  Pneumonia
  Polyomaviruses
  Pseudomonas Aeruginosa
  Rabies
  Respiratory Syncytial Virus (RSV)
  Rhinoviruses
  Rotavirus
  Rubella
  Salmonellosis
  Septicemia
  Shigellosis
  Staphylococcus Aureus
  Streptococci
  Syphilis
  Toxoplasmosis
  Trichomonas Vaginalis
  Tuberculosis
  Vibrio
  West Nile Virus
  Yersinia
  2. CANCER TESTING
    a. Overview
    b. Major Cancer Types
  Prostate
  Lung
  Colon and Rectum
  Breast
  Skin
  Uterine
  Leukemia
  Oral
    c. Oncogenes
  Abl/abl bcr
  AIB1
  BCL2
  BRCA1
  CD44
  C-fos
  C-myb
  C-myc
  CYP17
  ErbB
  HPC1
  Nmyc
  P40
  P51
  P53
  PIK3CA
  PTI1
  Ras
  Reg
  Sis
  Src
  3. GENETIC DISEASES
    a. Overview
    b. Nucleic Acid Amplification
    c. Chromosome Imaging
    d. Genomics Technologies
    e. Proteomics Technologies
    f. Current Pharmacogenomic Tests
    g. Future Pharmacogenomic Testing
    h. Major Diseases
  Achondroplasia
  Autosomal Dominant Polycystic Kidney Disease
  Cancer
  Cosmetogenomics
  Cystic Fibrosis
  Down's Syndrome
  Duchenne and Becker Muscular Dystrophy
  Factor V (Leiden)
  Factor IX Deficiency
  Fragile X Syndrome
  Heart Disease
  Hemochomatosis
  Hemophilia
  Huntington's Disease
  Maternal Fetal Incompatibility
  Multiple Endocrine Neoplasia
  Phenylketonuria (PKU)
  Polycystic Kidney Disease (PKD)
  Prenatal Screening
  Retinitis Pigmentosa
  Retinoblastoma
  Sickle Cell Anemia
  Spinal Muscular Atrophy
  Vitamin B12 Metabolism
    i. Social Issues and Concerns
  4. FORENSIC TESTING
    a. Overview
    b. Multilocus and Single Locus Probes
  Multilocus Probes
  Single Locus Probes
  PCR and RFLP
    c. DNA Profile Data Banks
    d. Judicial Implementation
    e. Major Crime Categories
    f. Factors Contributing to the DNA Probe Market Expansion
  Technology Availability
  Use of Hair as Evidence
    g. Wildlife Forensics
  5. PATERNITY TESTING/HLA TYPING
  6. OTHER APPLICATIONS
    a. Disease Susceptibility Testing
    b. Cardiovascular Diseases
    c. Diabetes
    d. Alzheimer's Disease
    e. Periodontal Disease
    f. Plasma Purification
    g. Organ Transplantation
    h. Water Contamination
    i. Other

9. MARKET SIZE AND GROWTH: TEST VOLUME AND SALES FORECASTS

10. COMPETITIVE ASSESSMENTS

  Abbott
  Agilent Technologies
  Applied Gene Technologies
  Arca Biopharma
  Beckman Coulter/Danaher
  Becton Dickinson
  Biokit
  bioMerieux
  Bio-Rad
  Biotest
  CellMark Forensics/LabCorp
  Cepheid
  Decode Genetics
  Diadexus
  Eiken
  Elitech Group
  Enzo
  Exact Sciences
  Fujirebio
  Grifols
  Hologic/Genrobe
  Illumina
  Kreatech/Leica
  Li Cor Biosciences
  Monogram Biosciences/LabCorp
  Myriad Genetics
  Ortho    Clinical Diagnostics
  Perkin Elmer/Caliper
  Proteome Sciences
  Qiagen
  Roche
  Scienion
  Sequenom
  Shimadzu
  Siemens
  Sierra Molecular
  Takara Bio
  Tecan Group
  Thermo Fisher/Affymetrix

11. APPENDIX: RESEARCH CENTERS DEVELOPING NEW TECHNOLOGIES AND PRODUCTS

List Of Tables

LIST OF TABLES

Molecular Diagnostics Test Volume and Sales Forecasts by Major Application Molecular Diagnostics Test Volume by Major Application Major Infectious Disease Test Volume by Assay Major Infectious Disease Test Volume by Method Molecular Diagnostics Market by Major Application Major Infectious Disease Diagnostics Market by Assay
Major Companies Developing or Marketing Salmonella Molecular Diagnostic Tests
Major Companies Developing or Marketing AIDS Molecular Diagnostic Tests
Major Companies Developing or Marketing Adenovirus Molecular Diagnostic Tests
Major Companies Developing or Marketing Bartonella Molecular Diagnostic Tests
Major Companies Developing or Marketing Campylobacter Molecular Diagnostic Tests
Major Companies Developing or Marketing Candida Molecular Diagnostic Tests
Major Companies Developing or Marketing Chlamydia Molecular Diagnostic Tests
Major Companies Developing or Marketing Clostridium Molecular Diagnostic Tests
Major Companies Developing or Marketing Coronavirus Molecular Diagnostic Tests
Major Companies Developing or Marketing Cryptosporidium Molecular Diagnostic Tests
Major Companies Developing or Marketing CMV Molecular Diagnostic Tests
Major Companies Developing or Marketing Echovirus Molecular Diagnostic tests
Major Companies Developing or Marketing Enterovirus Molecular Diagnostic tests
Major Companies Developing or Marketing EBV Molecular Diagnostic Tests
Major Companies Developing or Marketing Giardia Molecular Diagnostic Tests
Major Companies Developing or Marketing Gonorrhea Molecular Diagnostic Tests
Major Companies Developing or Marketing Hantavirus Molecular Diagnostic Tests
Major Companies Developing or Marketing Helicobacter Molecular Diagnostic Tests
Major Companies Developing or Marketing Hepatitis Molecular Diagnostic Tests
Major Companies Developing or Marketing Herpes Molecular Diagnostic Tests
Major Companies Developing or Marketing Influenza Molecular Diagnostic Tests
Major Companies Developing or Marketing Legionella Molecular Diagnostic Tests
Major Companies Developing or Marketing Lyme Disease Molecular Diagnostic Tests
Major Companies Developing or Marketing Measles Molecular Diagnostic Tests
Major Companies Developing or Marketing Meningitis Molecular Diagnostic Tests
Major Companies Developing or Marketing Mononucleosis Molecular Diagnostic Tests
Major Companies Developing or Marketing Mumps Molecular Diagnostic Tests
Major Companies Developing or Marketing Mycoplasma Molecular Diagnostic Tests
Major Companies Developing or Marketing Pneumonia Molecular Diagnostic Tests
Major Companies Developing or Marketing RSV Molecular Diagnostic Tests
Major Companies Developing or Marketing Rotavirus Molecular Diagnostic Tests
Major Companies Developing or Marketing Rubella Molecular Diagnostic Tests
Major Companies Developing or Marketing Septicemia Molecular Diagnostic Tests
Major Companies Developing or Marketing Shigella Molecular Diagnostic Tests
Major Companies Developing or Marketing Streptococci Molecular Diagnostic Tests
Major Companies Developing or Marketing Syphilis Molecular Diagnostic Tests
Major Companies Developing or Marketing Toxoplasmosis Molecular Diagnostic Tests
Major Companies Developing or Marketing Trichomonas Molecular Diagnostic Tests
Major Companies Developing or Marketing Tuberculosis Molecular Diagnostic Tests
Oncogenes Potential Application in Cancer Diagnosis
Major Companies Developing or Marketing Cancer Molecular Diagnostic Tests
Major Companies Developing or Marketing Molecular Diagnostic Tests For Genetic Diseases